Adam Bress, PharmD, MS
- Heart Failure
- Health Disparities
- Cardiovascular Disease Prevention and Treatment
- Departments: Population Health Sciences - Assistant Professor
- Divisions: Health System Innovation and Research
Academic Office Information
295 Chipeta Way
Salt Lake City, UT 84108
I am a clinical pharmacist with training in epidemiology and pharmacogenetics. I focus on disparities in prevention and treatment of cardiovascular disease. I use pharmacoepidemiology and pharmacogenetics to understand causes of racial differences in medication responses. We apply these findings to understand the population-level impact, generalizability, and cost-effectiveness in diverse groups
Dr. Bress is currently Assistant Professor of Population Health Sciences in the Division of Health System Innovation and Research and an Investigator at the VA Salt Lake City Health Care System.
Dr. Bress received his Doctor of Pharmacy degree from the University of Maryland, and his Masters of Science in Clinical and Translational Science from the University of Illinois at Chicago School of Public Health with a focus on epidemiology. He completed his residency in pharmacy practice at Yale-New Haven Hospital and Cardiology at the University of Illinois at Chicago. He subsequently completed his post-doctoral research fellowship in cardiovascular pharmacogenomics at the University of Illinois at Chicago.
Dr. Bress is a cardiovascular clinical pharmacist and population scientist whose research is focused on the prevention and treatment of cardiovascular disease. He is particularly interested in genetic ancestry and racial/ethnic differences in antihypertensive medication responses and population-level impact and generalizability of intensive blood pressure treatment. His research uses pharmacoepidemiology (drug effects in populations) and pharmacogenetics (genetic causes of variable drug effects) and aims to understand the complex issues surrounding race/ethnicity, genetic ancestry, and racial/ethnic differences in medication responses and outcomes. He is particularly interested in how genetic ancestry can be used to learn more about the multi-factorial causes of racial/ethnic differences in medication responses and health outcomes. After coming to the Universtiy of Utah, he received an NIH career development award investigating genetic and environmental causes of racial/ethnic differences in blood pressure medication responses and cardiovascular disease events.
Dr. Bress's research has been covered in TIME Magazine, The New York Times, and CBS radio and has produced a recommended article by F1000 prime.
Dr. Bress has received peer-reviewed extramural research support as Principal Investigator (PI) from the National Institutes of Health (NIH) specifically from the National Heart, Lung, and Blood Institute (NHLBI). He is currently PI of a five-year K01 award which is determining the association between genetic ancestry, including individual genetic variants, with blood pressure control, antihypertensive medication responses, and cardiovascular disease outcomes in African Americans. This project will identify genetic factors that may account for observed racial differences in antihypertensive medication response, potentially identify new approaches for optimizing antihypertensive medication prescribing and thereby improve blood pressure control rates in African Americans. His mentors and scientific advisors for this award are Lynn Jorde (human genetics), Rachel Hess (health services research), Rick Kittles (genetic ancestry and health disparities), Donna Arnett (pharmacogenetics), Paul Muntner (hypertension epidemiology), and Tom Greene (biostatistics).
He also received grant support from the biomedical industry as PI for investigator-initiated research projects focused on cardiovascular pharmacoepidemiology.
|Research Fellow||University of Illinois at Chicago
|Graduate Training||University of Illinois at Chicago School of Public Health
Clinical and Translational Science
|Residency||University of Illinois at Chicago
|Residency||Yale-New Haven Hospital
|Doctoral Training||University of Maryland
- Shallcross AJ, Butler M, Tanner RM, Bress A, Muntner P, Shimbo D, Ogedegbe G, Sims M, Spruill TM (2017). Psychosocial correlates of apparent treatment-resistant hypertension in the Jackson Heart Study.LID - 10.1038/jhh.2016.100 [doi]. (Epub ahead of print) J Hum Hypertens.
- King JB, Shah RU, Sainski-Nguyen A, Biskupiak J, Munger MA, Bress AP (2017). Effect of Inpatient Dobutamine vs. Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure.LID - 10.1002/phar.1939 [doi]. (Epub ahead of print) Pharmacotherapy.
- Bress AP, Colantonio LD, Booth JN 3rd, Spruill TM, Ravenell J, Butler M, Shallcross AJ, Seals SR, Reynolds K, Ogedegbe G, Shimbo D, Muntner P (2017). Modifiable Risk Factors Versus Age on Developing High Predicted Cardiovascular Disease Risk in Blacks.LID - e005054 [pii]LID - 10.1161/JAHA.116.005054 [doi]. J Am Heart Assoc, 6(2).
- Bress AP, Kramer H, Khatib R, Beddhu S, Cheung AK, Hess R, Bansal VK, Cao G, Yee J, Moran AE, Durazo-Arvizu R, Muntner P, Cooper RS (2017). Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey). Circulation, 135(17), 1617-1628.
- Kansal MM, Mansour IN, Ismail S, Bress A, Wu G, Mirza O, Marpadga R, Gheith H, Kim Y, Li Y, Cavallari L, Stamos TD (2017). Left ventricular global longitudinal strain predicts mortality and heart failure admissions in African American patients.LID - 10.1002/clc.22662 [doi]. (Epub ahead of print) Clin Cardiol.
- Ravenell JE, Shimbo D, Booth JN 3rd, Sarpong DF, Agyemang C, Beatty Moody DL, Abdalla M, Spruill TM, Shallcross AJ, Bress AP, Muntner P, Ogedegbe G (2017). Thresholds for Ambulatory Blood Pressure Among African Americans in the Jackson Heart Study.LID - CIRCULATIONAHA.116.027051 [pii]LID - 10.1161/CIRCULATIONAHA.116.027051 [doi]. (Epub ahead of print) Circulation.
- Bress AP, Tanner RM, Hess R, Gidding SS, Colantonio LD, Shimbo D, Muntner P (2016). Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups: Age <50 Years, Diabetes Mellitus, or a History of Stroke.LID - 10.1161/JAHA.116.003547 [doi]LID - e003547 [pii]. J Am Heart Assoc, 5(7).
- Tajeu GS, Kent ST, Kronish IM, Huang L, Krousel-Wood M, Bress AP, Shimbo D, Muntner P (2016). Trends in Antihypertensive Medication Discontinuation and Low Adherence Among Medicare Beneficiaries Initiating Treatment From 2007 to 2012. Hypertension, 68(3), 565-75.
- Stone RH, Bress AP, Nutescu EA, Shapiro NL (2016). Upper-Extremity Deep-Vein Thrombosis: A Retrospective Cohort Evaluation of Thrombotic Risk Factors at a University Teaching Hospital Antithrombosis Clinic.LID - 1060028016649601 [pii]. (Epub ahead of print) Ann Pharmacother.
- Brixner D, Biltaji E, Bress A, Unni S, Ye X, Mamiya T, Ashcraft K, Biskupiak J (2016). The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ, 19(3), 213-28.
- Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P (2016). Generalizability of SPRINT Results to the U.S. Adult Population. J Am Coll Cardiol, 67(5), 463-72.
- Mansour IN, Bress AP, Groo V, Ismail S, Wu G, Patel SR, Duarte JD, Kittles RA, Stamos TD, Cavallari LH (2016). Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure. J Card Fail, 22(9), 692-9.
- Bress AP, King JB, Brixner D, Kielhorn A, Patel HK, Maya J, Lee VC, Biskupiak J, Munger M (2016). Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center. Pharmacotherapy, 36(2), 174-86.
- King JB, Shah RU, Bress AP, Nelson RE, Bellows BK (2016). Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail, 4(5), 392-402.
- Bress A, Kittles R, Wing C, Hooker SE Jr, King A (2015). Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. Pharmacogenet Genomics, 25(6), 305-12.
- Sharabiani A, Bress A, Douzali E, Darabi H (2015). Revisiting Warfarin Dosing Using Machine Learning Techniques. Comput Math Methods Med, 2015, 560108.
- Biskupiak JE, Biltaji E, Bress A, Unni S, Ye X, Yu B, Mamiya T, Brixner D (2015). Value Assessment for Genetic Testing of Drug Variation In An Elderly Population. Value Health, 18(7), A747.
- Drozda K, Wong S, Patel SR, Bress AP, Nutescu EA, Kittles RA, Cavallari LH (2015). Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics, 25(2), 73-81.
- McConeghy KW, Bress A, Qato DM, Wing C, Nutescu EA (2014). Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Pharmacotherapy, 34(6), 561-9.
- DiDomenico RJ, Bress AP, Na-Thalang K, Tsao YY, Groo VL, Deyo KL, Patel SR, Bishop JR, Bauman JL (2014). Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure. Pharmacotherapy, 34(11), 1121-31.
- Bress A, Han J, Patel SR, Desai AA, Mansour I, Groo V, Progar K, Shah E, Stamos TD, Wing C, Garcia JG, Kittles R, Cavallari LH (2013). Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure. PLoS One, 8(7), e71268.
- Kane SP, Bress AP, Tesoro EP (2013). Characterization of unbound phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation. Ann Pharmacother, 47(5), 628-36.
- Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, Desai AA, Duarte JD, Gordeuk V, Peace D, Kadkol SS, Dodge C, Saraf S, Garofalo J, Krishnan JA, Garcia JG, Cavallari LH (2013). Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy, 33(11), 1156-64.
- Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH (2012). The effect of NAD(P)H dehydrogenase, quinone 1 (NQO1) genotype on warfarin dose requirements in Hispanic and African Americans. Pharmacogenomics, 13(16), 1939-49.
- Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH (2012). Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics, 13(16), 1925-35.
- Bress AP, Filtz MR, Truong HA, Nalder M, Vienet M, Boyle C (2011). An Advanced Pharmacy Practice Experience in Melbourne, Australia: Practical Guidance for Global Experiences. Curr Pharm Teach Learn, 1(3), 53-62.
- King JB, Bress AP, Reese AD, Munger MA (2015). Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review. [Review]. Pharmacotherapy, 35(9), 823-37.
- Cavallari LH, Jeong H, Bress A (2011). Role of cytochrome P450 genotype in the steps toward personalized drug therapy. [Review]. Pharmacogenomics and Personalized Medicine, 4, 123-36.
- Bress AP, Tanner RM, Hess R, Gidding SS, Colantonio LD, Shimbo D, Muntner P (2016). Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups [Abstract]. J Am Soc Hypertens, 10(1), e6-e7.
- Intensive Blood Pressure Control Could Prevent 100,000 Deaths Each Year
- Comprehensive Mentoring Program Builds Foundation for Success
- ER visits, hospitalizations decline in elderly patients evaluated by DNA testing and predictive medication analytics system
- How Low to Go for Blood Pressure? Lower Target Could Affect Millions of Americans